quanfu quanfu

Product Center

/
/
/
Subunit influenza vaccines for all age groups are now available for vaccination in Zhengzhou; individuals aged 6 months and older may receive them.

Subunit influenza vaccines for all age groups are now available for vaccination in Zhengzhou; individuals aged 6 months and older may receive them.

  • Categories:Industry news
  • Author:
  • Origin:
  • Time of issue:2026-09-22
  • Views:

(Summary description)On September 22, the "Influenza Vaccine Science Popularization Tour in China" event was held at the Wenhua Road Community Health Service Center in Zhengzhou. During this event, Huierkangxin 3—the first domestic influenza virus subunit vaccine covering all populations aged 6 months and older—was already available for vaccination. At the event, disease control experts, pediatric and clinical specialists, and community vaccination personnel conducted science popularization sessions on influenza epidemic trends, prevention and control measures for key populations, vaccination practices, and the technical characteristics of subunit vaccines.

Subunit influenza vaccines for all age groups are now available for vaccination in Zhengzhou; individuals aged 6 months and older may receive them.

(Summary description)On September 22, the "Influenza Vaccine Science Popularization Tour in China" event was held at the Wenhua Road Community Health Service Center in Zhengzhou. During this event, Huierkangxin 3—the first domestic influenza virus subunit vaccine covering all populations aged 6 months and older—was already available for vaccination. At the event, disease control experts, pediatric and clinical specialists, and community vaccination personnel conducted science popularization sessions on influenza epidemic trends, prevention and control measures for key populations, vaccination practices, and the technical characteristics of subunit vaccines.

  • Categories:Industry news
  • Author:
  • Origin:
  • Time of issue:2026-09-22 15:21
  • Views:
Information

Visual Omnimedia Center of Henan Daily; Reporter Yang Guang, Dahe Daily

On September 22, the "Influenza Vaccine Science Popularization Tour in China" event was held at the Wenhua Road Community Health Service Center in Zhengzhou. During this event, Huierkangxin 3—the first domestic influenza virus subunit vaccine covering all populations aged 6 months and older—was already available for vaccination. At the event, disease control experts, pediatric and clinical specialists, and community vaccination personnel conducted science popularization sessions on influenza epidemic trends, prevention and control measures for key populations, vaccination practices, and the technical characteristics of subunit vaccines.

According to reports, influenza is an acute respiratory infectious disease caused by the influenza virus. It is highly contagious, spreads rapidly, and can lead to complications such as pneumonia, myocarditis, and encephalitis; infants, elderly individuals, people with chronic diseases, pregnant women, and those with compromised immune systems face a relatively higher risk of developing severe illness upon infection.

During the event, Lu Mingxia, director of the First Division of the Immunization Program Office at the Henan Provincial Center for Disease Control and Prevention, stated that this year the national government has secured funding through multiple channels—including fiscal funds, individual medical insurance accounts of employees, and trade union funds—to support vaccination efforts for key population groups. She noted that protective antibodies typically take 2–4 weeks to develop following vaccination, and since the peak influenza season in northern China generally occurs during winter and spring, she advised the public—particularly vulnerable groups such as the elderly and young children, as well as individuals with chronic diseases—to receive vaccinations as early as possible.

Song Chunlan, director of the Emergency Medicine Department at the South Campus of Henan Provincial Children's Hospital, emphasized that influenza is distinct from the common cold. Given that the immune systems of infants and young children are not yet fully developed, infection in this population can readily progress to severe complications such as severe pneumonia, fulminant myocarditis, and necrotizing encephalitis. The hospitalization rate for influenza-related conditions among children aged 0–4 years is 5.5 times higher than that of the general population. She noted that the primary objective of influenza vaccination is not to prevent infection per se, but rather to significantly reduce the risk of severe disease and mortality.

When faced with influenza vaccines based on different technological platforms, how should the public make their choice? According to the "Technical Guidelines for Influenza Vaccination in China (2026–2027)", the trivalent influenza vaccines available in China during the 2026–2027 period include trivalent inactivated vaccines and trivalent live attenuated vaccines. Among the inactivated vaccines, there are two types: split vaccines and subunit vaccines, which can be used in individuals aged 6 months and older; the live attenuated vaccines are suitable for individuals aged 3–17 years.

Song Chunlan explained that both lysate vaccines and subunit vaccines represent well-established and effective technological approaches. Subunit vaccines are further purified based on lysate technology, offering relatively higher safety profiles. She advised that parents may, under medical guidance, make a choice regarding which vaccine to administer by considering the child's age, health status, prior vaccination history, and professional assessment conducted by the vaccination clinic.

According to publicly available information from the National Medical Products Administration (NMPA), Jiangsu Zhonghui Biotech's quadrivalent influenza virus subunit vaccine was approved for market launch in 2023. In 2026, the influenza virus subunit vaccine "Hui' er Kangxin 3" will also be approved for market launch, thereby extending full population coverage to individuals aged 6 months and older. A senior representative of the company stated that the company will collaborate with multiple stakeholders to conduct effective public education campaigns, ensuring that innovative achievements in domestically produced vaccines benefit a broader segment of the population.

Scan the QR code to read on your phone

Relevant information

Got a project? Contact us today !

At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.

Contact

E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City

Copyright © 2022 Ab&B Bio-Tech CO.,LTD.JS All Rights Reserved.   Powered by:www.300.cn
Search